Hims & Hers (HIMS) Form 4: Director sells 10,021 shares under 10b5-1 plan

Q: What did the HIMS insider sell on 09/17/2025?

The insider sold 10,021 Class A common shares at $50.50 per share on 09/17/2025 .

Q: Who filed the Form 4 for HIMS on behalf of Patrick Harrison Carroll?

The Form 4 was signed by Kimberly Mather, Attorney-in-Fact for Patrick Harrison Carroll on 09/19/2025 .

Q: What insider roles does Patrick Harrison Carroll hold at HIMS?

The Form 4 indicates he is a Director and an Officer with the title Chief Medical Officer .

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Patrick Harrison Carroll, a director and the company's Chief Medical Officer at Hims & Hers Health, Inc. (HIMS), reported a sale of 10,021 shares of Class A common stock on 09/17/2025 at a price of $50.50 per share. After the transaction he beneficially owned 169,940 shares, reported as direct ownership. The filing states the sales were executed under a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2025. The Form 4 was signed by an attorney-in-fact on 09/19/2025. The filing discloses the insider relationship and the exact transaction details without additional commentary.

Positive

Transaction fully disclosed with date, price, quantity, and post-transaction holdings
Sale executed under a Rule 10b5-1 trading plan, indicating a prearranged framework for trades
Reporting person identified as Director and Chief Medical Officer, clarifying insider status

Negative

Reduction of direct holdings by 10,021 shares as of 09/17/2025
Sale price $50.50 realized on the disposed shares (cash proceeds implied but not stated explicitly)

Insights

TL;DR Insider sold 10,021 shares at $50.50 under a prearranged 10b5-1 plan; remaining direct holding is 169,940 shares.

The sale is clearly documented with transaction date, price, and post-transaction holdings, which supports transparency for market monitoring. The use of a 10b5-1 plan indicates the trades were pre-authorized, reducing the likelihood they were based on material non-public information. The filing does not provide information on the percentage of outstanding shares or any change in role or compensation.

TL;DR Form 4 properly discloses insider status, transaction details, and reliance on a 10b5-1 plan, meeting disclosure expectations.

The report identifies the reporting person as both a director and officer and specifies the nature of the transaction and plan adoption date. Signature by an attorney-in-fact is noted. The filing contains no governance concerns beyond the disclosed sale; it does not report amendments or additional arrangements.

Insider Trade Summary

Net Seller: 10,021 shares ($506,061)

Net Sell 1 txn

Insider Carroll Patrick Harrison

Role Chief Medical Officer

Sold 10,021 shs ($506K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	10,021	$50.50	$506K

Holdings After Transaction: Class A Common Stock — 169,940 shares (Direct)

Footnotes (1)

[object Object]

Form 4 Insider Transactions: What Each Field Means →

09/19/2025 - 04:28 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Carroll Patrick Harrison

(Last)

(First)

(Middle)

2269 CHESTNUT STREET, #523

(Street)

SAN FRANCISCO

94123

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Hims & Hers Health, Inc. [ HIMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	09/17/2025		S⁽¹⁾		10,021	D	$50.5	169,940	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 19, 2025 by the Reporting Person.

Remarks:

	/s/ Kimberly Mather, Attorney-in-Fact for Patrick Harrison Carroll	09/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did the HIMS insider sell on 09/17/2025?

The insider sold 10,021 Class A common shares at $50.50 per share on 09/17/2025.

Who filed the Form 4 for HIMS on behalf of Patrick Harrison Carroll?

The Form 4 was signed by Kimberly Mather, Attorney-in-Fact for Patrick Harrison Carroll on 09/19/2025.

How many HIMS shares does the reporting person beneficially own after the sale?

After the reported transaction the reporting person beneficially owned 169,940 shares (direct ownership).

Was the sale part of a prearranged trading plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on May 19, 2025.

What insider roles does Patrick Harrison Carroll hold at HIMS?

The Form 4 indicates he is a Director and an Officer with the title Chief Medical Officer.